August 3, 2026
Published August 2026
For decades, MedTech companies operated on a predictable — if frustrating — rhythm: win FDA clearance or approval, then spend the next twelve months or more navigating the separate, often opaque world of Medicare coverage. Regulatory and market access were sequential functions. You could staff them that way too.
That model is over.
On April 23, 2026, the Centers for Medicare & Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) jointly announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway. The program is designed to issue a proposed National Coverage Determination (NCD) on the very same day an eligible device receives FDA market authorization — compressing what has historically been a twelve-month-or-longer wait into as little as sixty to ninety days.
The gap between regulatory approval and reimbursement has always been where MedTech revenue goes to die. RAPID is closing it. And that changes everything about how you need to build your team.
RAPID is a joint CMS-FDA initiative targeting Class II and Class III devices that have received FDA Breakthrough Device designation. For eligible devices, CMS commits to issuing a proposed NCD at the moment of FDA market authorization, triggering a statutorily required 30-day public comment period. The result: permanent national Medicare coverage could take effect roughly two months after FDA clears or approves the device — compared to the year or more it typically takes today.
This isn't a reimbursement shortcut. It's a structural redesign of how coverage evidence gets built and evaluated. To qualify, a device must meet several specific requirements:
That last requirement is the inflection point.
Currently, approximately 40 devices qualify for RAPID right now, with roughly 20 more potentially eligible. But the real significance isn't today's number — it's that every Breakthrough Device company now has to think about Medicare coverage strategy at the same time it's designing its IDE study.
Here's the operational challenge RAPID creates: your pivotal clinical trial — the one you've always designed with FDA in mind — must now simultaneously satisfy CMS's evidence requirements for a coverage determination.
As companies design their IDE studies with the FDA, CMS will coordinate to ensure those studies collect the clinical evidence required for a Medicare coverage determination. In some cases, CMS may also require post-market evidence generation, either through FDA-required post-market approval studies or other post-market surveillance, with coverage tied to continuing evidence development.
This is not a regulatory affairs problem. It's not purely a clinical affairs problem either. It's a market access problem — and it has to be solved before your first patient is enrolled.
Your market access lead needs to be at the table when you're writing your IDE protocol. They need to understand not just what FDA requires for safety and efficacy, but what CMS needs to make a coverage determination. They need fluency in both regulatory science and health economics. They need relationships and enough policy literacy to anticipate how a proposed NCD will land during the 30-day public comment window. And they need to be hired, onboarded, and operating long before your pivotal trial starts — because once the IDE design is locked, the leverage is gone.
The sequential staffing model — hire regulatory first, worry about reimbursement later — is now a liability.
RAPID doesn't exist in a vacuum. In the same April 2026 regulatory cycle, CMS also proposed to repeal the NTAP Alternative Pathway for Breakthrough Devices as part of the FY 2027 Inpatient Prospective Payment System (IPPS) proposed rule. If finalized, this takes effect in FY 2028.
The NTAP (New Technology Add-On Payment) Alternative Pathway had allowed Breakthrough Devices to receive hospital add-on payments without meeting the traditional substantial clinical improvement standard. Under the proposal, devices with Breakthrough designation would have to meet the same NTAP eligibility criteria as any other technology to receive those additional payments.
These two proposals — accelerated NCD coverage via RAPID, combined with the removal of the NTAP shortcut — send a consistent signal: CMS is raising the evidentiary bar for Breakthrough Devices while simultaneously committing to faster coverage decisions for those that clear it. Speed as a reward for rigor.
The companies positioned to win under this framework are the ones who understand both sides of that equation. That understanding lives in your market access function.
If you have a Breakthrough Device in development — or are pursuing the designation — the following capabilities now need to exist inside your organization well before your IDE study is designed:
Evidence strategy at the intersection of FDA and CMS. Someone who can read an IDE protocol and immediately identify whether it generates the data CMS needs for a coverage determination. This is a rare skill set. It requires clinical, regulatory, and health economics literacy simultaneously.
Health economics and outcomes research (HEOR). RAPID's evidence requirements will, in many cases, extend into post-market studies. Building a durable coverage argument means understanding cost-effectiveness, quality of life endpoints, and how payers think about value — from the very start of your clinical program.
Policy and coverage expertise. The 30-day public comment period on a proposed NCD is not an administrative formality. Payers, providers, and patient advocacy groups will weigh in. Having someone who understands how to navigate that process — and how to shape the evidence narrative ahead of it — is now a competitive advantage.
Cross-functional integration. Market access in the RAPID era isn't a downstream commercial function. It sits at the intersection of R&D, regulatory affairs, clinical operations, and commercial strategy. The hire you make needs the credibility and range to operate across all of them.
AdvaMed, the industry's leading trade group, has supported RAPID as a meaningful step toward expanding patient access to breakthrough technology — while noting that without accountability and effective program management, patients may not see the full benefit. The same is true inside your company. A great regulatory dossier with a weak coverage strategy won't get you there.
RAPID is still a proposed framework, subject to further development and refinement by CMS and FDA. But the direction is clear, and the companies that wait until it's finalized to build their market access capability will already be behind.
The MedTech companies that win in the RAPID era will be the ones that treat market access not as a post-FDA function, but as a foundational discipline — one that shapes clinical strategy, informs trial design, and builds the evidentiary record that makes national coverage possible on day one of authorization.
That starts with the right hire. And that hire needs to happen now.
Sources:
© All rights reserved